![]() |
|
|
Vol. 289, Issue 1, 285-294, April 1999
Departments of
Psychiatry and Behavioral Sciences (S.M.E., R.R.G.)
and
Neuroscience (R.R.G.), The Johns Hopkins University School of
Medicine, Baltimore, Maryland
Although caffeine is the most widely used behaviorally active drug in
the world, caffeine physical dependence has been only moderately well
characterized in humans. Four double-blind experiments were conducted
in independent groups of healthy participants to assess the conditions
under which withdrawal symptoms occur upon cessation of low to moderate
doses of caffeine. In experiment 1, there was no evidence that the
range or magnitude of caffeine withdrawal symptoms differed when 300 mg
of caffeine was consumed as a single dose in the morning versus 100 mg
at three time points across the day. In experiment 2, both the range
and severity of withdrawal increased as a function of caffeine
maintenance dose (100, 300, and 600 mg/day), with even the lowest dose
(100 mg) producing significant caffeine withdrawal. Experiment 3 showed that when individuals were maintained on 300 mg caffeine/day and tested
with a range of lower doses (200, 100, 50, 25, and 0 mg/day), a
substantial reduction in caffeine consumption (
100 mg/day) was
necessary for the manifestation of caffeine withdrawal. Experiment 4 manipulated duration of exposure to caffeine (1, 3, 7, or 14 days of
300 mg/day) and showed that caffeine withdrawal occurred after as
little as 3 days of caffeine exposure, with a somewhat increased
severity of withdrawal observed after 7 or 14 days of exposure. As a
whole, this set of experiments provides the most complete parametric
characterization of caffeine withdrawal to date and suggests that
caffeine physical dependence can occur under more modest conditions
(i.e., fewer doses per day, lower daily dose, shorter duration of
exposure) than previously recognized.
This article has been cited by other articles:
![]() |
A. Bassini-Cameron, E. Sweet, A. Bottino, C. Bittar, C. Veiga, L.-C. Cameron, and E. H M Dantas Effect of caffeine supplementation on haematological and biochemical variables in elite soccer players under physical stress conditions * COMMENTARY Br. J. Sports Med., August 1, 2007; 41(8): 523 - 530. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Haskell, D. O. Kennedy, K. A. Wesnes, A. L. Milne, and A. B. Scholey A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guarana in humans J Psychopharmacol, January 1, 2007; 21(1): 65 - 70. [Abstract] [PDF] |
||||
![]() |
W. R. Lovallo, T. L. Whitsett, M. al'Absi, B. H. Sung, A. S. Vincent, and M. F. Wilson Caffeine Stimulation of Cortisol Secretion Across the Waking Hours in Relation to Caffeine Intake Levels Psychosom Med, September 1, 2005; 67(5): 734 - 739. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. James Critical Review of Dietary Caffeine and Blood Pressure: A Relationship That Should Be Taken More Seriously Psychosom Med, January 1, 2004; 66(1): 63 - 71. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Biaggioni and S. N. Davis Caffeine: A Cause of Insulin Resistance? Diabetes Care, February 1, 2002; 25(2): 399 - 400. [Full Text] [PDF] |
||||
![]() |
R. R. Griffiths and E. M. Vernotica Is Caffeine a Flavoring Agent in Cola Soft Drinks? Arch Fam Med, August 1, 2000; 9(8): 727 - 734. [Abstract] [Full Text] [PDF] |
||||